Antiviral product, use and formulation thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/00
A61K-009/48
A61K-009/20
A61K-009/16
출원번호
US-0273661
(2005-11-14)
등록번호
US-7282221
(2007-10-16)
발명자
/ 주소
Rudnic,Edward M.
Isbister,James D.
Treacy, Jr.,Donald J.
Wassink,Sandra E.
출원인 / 주소
Middlebrook Pharmaceuticals, Inc.
인용정보
피인용 횟수 :
4인용 특허 :
266
초록▼
An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed relea
An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
대표청구항▼
What is claimed is: 1. A once-a-day antiviral product comprising: first, second, and third antiviral dosage forms, each of said antiviral dosage forms comprising at least one antiviral and a pharmaceutically acceptable carrier, said first antiviral dosage form being an immediate release dosage form
What is claimed is: 1. A once-a-day antiviral product comprising: first, second, and third antiviral dosage forms, each of said antiviral dosage forms comprising at least one antiviral and a pharmaceutically acceptable carrier, said first antiviral dosage form being an immediate release dosage form, said second and third antiviral dosage forms being delayed release dosage forms wherein at least one of said second or third dosage forms is a non-pH sensitive dosage form, and wherein each of said first, second, and third antiviral dosage forms initiates release at different times and Cmax in serum of the total antiviral released from said antiviral product is achieved in less than about 12 hours from administration and said once-a-day antiviral product contains the total dosage of the at least one antiviral for a twenty-four hour period. 2. The product of claim 1, wherein the Cmax for the product is reached no earlier than four hours after administration. 3. The product of claim 1, wherein the antiviral released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product. 4. The product of claim 1, wherein the antiviral released from the second dosage form reaches a Cmax in no more than about 4 hours after administration of the product. 5. The product of claim 1, wherein the antiviral released from the third dosage form reaches a Cmax within 8 hours after administration of the product. 6. The product of claim 1, wherein the immediate release dosage form contains at least 20% and no more than 50% of the total dosage of antiviral. 7. The product of claim 1, wherein the product is an oral dosage form. 8. The product of claim 7, wherein the antiviral released from the second dosage form reaches a Cmax after Cmax is reached for the antiviral released from the first dosage form. 9. The product of claim 8, wherein the antiviral released from the third dosage form reaches a Cmax after Cmax is reached for the antiviral released from the second dosage form. 10. The product of claim 1, wherein said second dosage form initiates release of said antiviral before said third dosage form, wherein said second dosage form provides from 30% to 60% by weight of the total antiviral released by said second and third dosage forms, and wherein said third dosage form provides the remainder of the total antiviral released by said second and third dosage forms. 11. The product of claim 1 further comprising a fourth antiviral dosage form, said fourth antiviral dosage form comprising at least one antiviral and a pharmaceutically acceptable carrier and wherein said at least one antiviral released from said fourth antiviral dosage form reaches a Cmax in the serum after Cmax is achieved in the serum for antiviral released from each of said first, second, and third dosage forms. 12. The product of claim 11, wherein said fourth antiviral dosage form is a delayed release dosage form. 13. The product of claim 11, wherein the Cmax for the product is reached no earlier than four hours after administration. 14. The product of claim 11, wherein the antiviral released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product. 15. The product of claim 11, wherein the antiviral released from the second dosage form reaches a Cmax in no more than about 4 hours after administration of the product. 16. The product of claim 11, wherein the antiviral released from the third dosage form reaches a Cmax within 8 hours after administration of the product. 17. The product of claim 11, wherein said second dosage form initiates release of antiviral before said third dosage form, wherein said third dosage form initiates release of antiviral before said fourth dosage form, wherein said second dosage form provides 20% to 35% by weight of the total antiviral released by said second, third, and fourth dosage forms, wherein said third dosage form provides from 20% to 40% by weight of the total antiviral released by said second, third, and fourth dosage forms, and wherein said fourth dosage form provides the remainder of the total antiviral released by said second, third, and fourth dosage forms. 18. The product of claim 11, wherein the product is an oral dosage form. 19. The product of claim 11, wherein the antiviral released from the second dosage form reaches a Cmax after Cmax is reached for the antiviral released from the first dosage form. 20. The product of claim 11, wherein the antiviral released from the third dosage form reaches a Cmax after Cmax is reached for the antiviral released from the second dosage form. 21. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 1, once-a-day. 22. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 2, once-a-day. 23. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 3, once-a-day. 24. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 4, once-a-day. 25. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 5, once-a-day. 26. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 6, once-a-day. 27. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 7, once-a-day. 28. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 8, once-a-day. 29. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 9, once-a-day. 30. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 10, once-a-day. 31. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 11, once-a-day. 32. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 12, once-a-day. 33. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 13, once-a-day. 34. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 14, once-a-day. 35. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 15, once-a-day. 36. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 16, once-a-day. 37. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 17, once-a-day. 38. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 18, once-a-day. 39. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 19, once-a-day. 40. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 20, once-a-day. 41. The once-a-day antiviral product of claim 1, wherein the antiviral is in the form of a salt. 42. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 41, once-a-day. 43. A process for treating a patient with an antiviral agent said process for treating comprising: administering to a patient once-a-day an antiviral product, said product comprising: first, second, and third dosage forms, wherein each of said dosage forms includes at least one antiviral agent and a pharmaceutically acceptable carrier; said treating including an immediate release of antiviral agent from said first dosage form and delayed releases of antiviral agent from each of said second and third dosage forms, wherein at least one of said second or third dosage forms is a non-pH sensitive dosage form, said immediate release and two delayed releases initiating release of antiviral agent at different times to produces a Cmax in serum of the total antiviral agent released from said antiviral product in less than about 12 hours from administration; and said treating delivers the total dosage of said at least one antiviral agent for a twenty-four hour period. 44. A once-a-day antiviral product comprising: first, second, and third antiviral dosage forms, each of said antiviral dosage forms comprising at least one antiviral agent and a pharmaceutically acceptable carrier, said first antiviral dosage form being an immediate release dosage form, said second and third antiviral dosage forms being delayed release dosage forms, wherein each of said second and third delayed release dosage forms comprise an immediate release dosage form and a member independently selected from the group consisting of: pH-sensitive components and non-pH-sensitive components to delay the release of the antiviral agent, wherein each of said first, second, and third antiviral dosage forms initiates release at different times, wherein Cmax in serum of the total antiviral agent released from said antiviral product is achieved in less than about 12 hours from administration, and said once-a-day antiviral product contains the total dosage of the at least one antiviral agent for a twenty-four hour period. 45. A process for treating a viral infection in a host comprising: administering to a host the antiviral product of claim 44 once-a-day.
Hancock, Robert E. W.; Gough, Monisha A.; Patrzykat, Aleksander; Woods, Donald; Jia, Xiaoyan, Anti-endotoxic antimicrobial cationic peptides and methods of use therfor.
Moenning Stephen P., Apparatus and method for protecting a port site opening in the wall of a body cavity utilizing a sealing member and a biologically active compound.
Chungi, Shubha; Iorio, Theodore L., Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin.
Elger Gordon A. (Huntingdon GBX) Leslie Stewart T. (Cambridge GBX) Malkowska Sandra T. A. (Landbeach GBX) Miller Ronald B. (Basel CHX) Neale Philip J. (Cambridge GBX), Controlled release pharmaceutical composition.
Yang S. Shirley (Succasunna NJ) Boisvert Wayne (Randolph NJ) Muhammad Nouman A. (Long Valley NJ) Weiss Jay (East Brunswick NJ), Controlled release tacrine drug delivery systems and methods for preparing same.
Rhodes John (25 Nantfawr Road Cyncoed ; Cardiff ; South Glamorgan CF2 6JO GBX) Evans Brian K. (9 Merevale ; The Common Dinas Powis ; South Glamorgain CF6 4HS GBX), Delayed release oral dosage forms for treatment of intestinal disorders.
Rivett Ernest Lionel Gilbert,GBX ; Grimmett Francis Walter,GBX ; Hartnell Michael William,GBX, Delayed release pharmaceutical formulation containing a .beta.-lactam antibiotic.
Jordan Maureen L. (Mt. View CA) Ayer Atul D. (Palo Alto CA) Magruder Paul R. (Palo Alto CA) Edgren David E. (El Granada CA), Dosage form for delivering acetaminophen or phenylpropanolamine.
Monkhouse Donald ; Yoo Jaedeok ; Sherwood Jill K. ; Cima Michael J. ; Bornancini Esteban, Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof.
Greco Ralph S. (Princeton NJ) Harvey Richard A. (East Brunswick NJ) Trooskin Stanley Z. (North Brunswick NJ), Drug bonded prosthesis and process for producing same.
Henley, Julian L.; Chang, Kuo Wei; Potter, Joseph; Goldberg, Dennis I.; Porter, Christopher H.; Porcelli, V. Lorenzo, Electrokinetic delivery of medicaments.
Gudipati, Manga R; Jushchyshyn, John M; Palepu, Nageswara R; Venkatesh, Gopadi M, Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation.
Mehta Atul M. (Ramsey NJ) Bachand Lizbeth A. (Plattsburgh NY) Leonard Thomas W. (Plattsburgh NY) Warner Ronald N. (Grand Isle VT), Formulations providing three distinct releases.
Mehta Atul M. (Ramsey NJ) Bachand Lizbeth A. (Plattsburgh NY) Leonard Thomas W. (Plattsburgh NY) Warner Ronald N. (Grand Isle VT), Formulations providing three distinct releases.
Mehta Atul M. (Ramsey NJ) Bachand Lizbeth A. (Plattsburgh NY) Leonard Thomas W. (Plattsburgh NY) Warner Ronald N. (Grand Isle VT), Formulations providing three distinct releases.
Czernielewski Janusz,FRX ; Allec Josiane,FRX ; Bouclier Martine,FRX, Medicaments based on metronidazole or on a synergic mixture of metronidazole and clindamycin.
Arvesen James N. (Princeton NJ), Method and apparatus for determining the minimum concentration of antibiotic necessary to at least inhibit microorganism.
Smith James W. (Indianapolis IN) Bartlett Marilyn S. (Indianapolis IN) Queener Sherry F. (Indianapolis IN), Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine.
Shimamura Tadakatsu (4-4 ; Nishihara 1-chome ; Shibuya-ku Tokyo JPX), Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus .
Cagle, Gerald; Abshire, Robert L.; Stroman, David W.; McLean, Celeste H.; Clark, Linda L.; Yanni, John M., Methods for treating otic and ophthalmic infections.
Moro, Daniel G.; Callahan, Howard; Nowotnik, David, Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds.
Wong Patrick S. L. (Palo Alto CA) Theeuwes Felix (Los Altos CA) Eckenhoff James B. (Los Altos CA) Larsen Steven D. (Dublin CA) Huynh Hoa T. (Fremont CA), Multi-unit delivery system.
Raad Isaam (Houston TX) Sherertz Robert (Winston-Salem NC), Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and.
Burnside Beth A. ; Guo Xiaodi ; Fiske Kimberly ; Couch Richard A. ; Treacy Donald J. ; Chang Rong-Kun ; McGuinness Charlotte ; Rudnic Edward M., Oral pulsed dose drug delivery system.
Burnside, Beth A.; Guo, Xiaodi; Fiske, Kimberly; Couch, Richard A.; Treacy, Donald J.; Chang, Rong-Kun; McGuinness, Charlotte M.; Rudnic, Edward M., Oral pulsed dose drug delivery system.
Infeld Martin H. (Upper Montclair NJ) Malick A. Waseem (Edison NJ) Shah Navnit H. (Clifton NJ) Phuapradit Wantanee (Kearny NJ), Pharmaceutical compositions with constant erosion volume for zero order controlled release.
Amano Takehiro (Urawa JPX) Goi Masami (Saitama JPX) Sekiuchi Kazuto (Tatebayashi JPX) Yoshida Tomomichi (Omiya JPX) Hasegawa Masahiro (Omiya JPX), Process for preparing erythromycin A oxime or a salt thereof.
Patt Tom E. (Kalamazoo MI) Argoudelis Alexander D. (Portage MI) Marshall Vincent P. (Kalamazoo MI), Process for preparing lincomycin and clindamycin ribonucleotides.
D'Silva, Joe, Process for producing liquid dosage formulations of medicinal compounds on demand from tablets and capsules using a mixing cup with an abrasive interior surface.
Ku Yi-Yin ; Riley David A. ; Lee Elaine C. ; Tien Jien-Heh, Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives.
Avrutov, Ilya; Lifshitz, Igor; Borochovitz, Ronen; Masarwa, Basem; Schwartz, Edi, Processes for preparing clarithromycin polymorphs and novel polymorph IV.
Panoz Donald (Tuckerstown BMX) Corneille Gilbert (Paris FRX), Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained the.
Wong Patrick S. L. ; Dong Liang-Chang ; Edgren David E. ; Theeuwes Felix ; Gardner Phyllis I. ; Jao Francisco ; Wan Jason J., Prolonged release active agent dosage form adapted for gastric retention.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Elmhurst NY) Gaylord Norman G. (New Providence NJ), Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose.
Sheth Nitin V. (Middletown NY) Valorose ; Jr. Joseph J. (Montgomery NY) Ellway Keith A. (Washingtonville NY) Ganesan Madurai G. (Suffern NY) Mooney Kieran G. (Warwick NY) Johnson Jerry B. (Upper Rive, Pulsatile once-a-day delivery systems for minocycline.
Baron ; Jr. Joseph J. (Morris Plains NJ) Nowakowski Tamara (Boonton Township ; Morris County NJ) Farrington Thomas A. (Sparta NJ) Mahn Frederick R. (Verona NJ), Retention and/or drainage and/or dewatering aid.
Philippe Michel (Antony FRX) Sebag Henri (Paris FRX) Dupuis Didier (Le Raincy FRX) Rougier Andr (Dammartin en Goele FRX), Retinoic esters of antibiotics and pharmaceutical and cosmetic compositions containing them.
Johnson Donald A. (Miami Lakes FL) Wearley Lorraine (Westfield NJ) Galeos Rebecca (Bloomfield NJ) Sequeira Joel A. (New York NY), Stable hydrated cephalosporin dry powder for oral suspension formulation.
Christensen Burton G. ; Cho In-Seop ; Glinka Tomasz W. ; Hecker Scott J., Substituted-pyridinyl cephalosporin antibiotics active against methicillin resistant bacteria.
Cima Michael (Lexington MA) Sachs Emanuel (Somerville MA) Fan Tailin (Cambridge MA) Bredt James F. (Watertown MA) Michaels Steven P. (Melrose MA) Khanuja Satbir (Cambridge MA) Lauder Alan (Boston MA), Three-dimensional printing techniques.
Sachs Emanuel M. (Somerville MA) Haggerty John S. (Lincoln MA) Cima Michael J. (Lexington MA) Williams Paul A. (Concord MA), Three-dimensional printing techniques.
Sachs Emanuel M. (Somerville) Haggerty John S. (Lincoln) Cima Michael J. (Lexington) Williams Paul A. (Concord MA), Three-dimensional printing techniques.
Stiefel Werner K. (Coral Gables FL) Popp Karl F. (Schodack Landing NY), Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof.
Bax Richard Peregrine,GBX, Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment drug-resistant Streptococcus pneumoniae.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.